* have a history of severe systemic reactions (anaphylaxis, breathing difficulties, severe rash) following previous immunization with licensed or unlicensed vaccines. * received an experimental agent within 30 days prior to the study vaccination or expect to receive another experimental agent during the trial-reporting period. * intend to receive another covid-19 vaccine during the time of the study

* have a history of severe systemic reactions (anaphylaxis, breathing difficulties, severe rash) following previous immunization with licensed or unlicensed vaccines. * received an experimental agent within 30 days prior to the study vaccination or expect to receive another experimental agent during the trial-reporting period. * intend to receive another covid-19 vaccine during the time of the study

have a history of severe systemic reactions (anaphylaxis, breathing difficulties, severe rash) following previous immunization with licensed or unlicensed vaccines. received an experimental agent within 30 days prior to the study vaccination or expect to receive another experimental agent during the trial-reporting period. intend to receive another covid-19 vaccine during the time of the study

have a history of severe systemic reactions (anaphylaxis, breathing difficulties, severe rash) following previous immunization with licensed or unlicensed vaccines. received an experimental agent within 30 days prior to the study vaccination or expect to receive another experimental agent during the trial-reporting period. intend to receive another covid-19 vaccine during the time of the study

have a history of severe systemic reactions (anaphylaxis, breathing difficulties, severe rash) following previous immunization with licensed or unlicensed vaccines. have a history of abnormal blood clotting or thrombocytopenia received an experimental agent within 30 days prior to the study vaccination or expect to receive another experimental agent during the trial-reporting period. intend to receive another covid-19 vaccine during the time of the study

have a history of severe systemic reactions (anaphylaxis, breathing difficulties, severe rash) following previous immunization with licensed or unlicensed vaccines. have a history of abnormal blood clotting or thrombocytopenia received an experimental agent within 30 days prior to the study vaccination or expect to receive another experimental agent during the trial-reporting period. intend to receive another covid-19 vaccine during the time of the study